Full-Time

Senior Director Epidemiology and Real World Evidence

Epidemiology and Real World Evidence

Dyne Therapeutics

Dyne Therapeutics

201-500 employees

Develops muscle-disease therapies using FORCE platform

Compensation Overview

$245k - $300k/yr

Waltham, MA, USA

In Person

On-site role in Waltham, MA; travel up to 30%.

Category
Biology & Biotech (1)
Required Skills
biometrics

Get referred to Dyne Therapeutics

Find people who can refer or advise you

Requirements
  • Advanced degree in epidemiology, public health, health services research, or a related discipline
  • 15+ years of relevant experience in epidemiology, real world evidence, observational research, or related scientific disciplines; or equivalent combination of education and experience
  • Deep expertise in epidemiologic methods, observational study design, real world data sources, and application of RWE to safety surveillance and pharmacovigilance
  • Demonstrated experience leading post-authorization safety studies and contributing to regulatory documentation
  • Proven ability to partner effectively across Medical Affairs, Clinical Development, Drug Safety/Pharmacovigilance, HEOR, Regulatory Affairs, and Market Access in a matrix environment
  • Strong track record of scientific communication, peer-reviewed publication, and external scientific engagement
  • Experience in rare diseases and/or neuromuscular disorders strongly preferred
  • Strong analytical, strategic, and problem-solving skills with the ability to operate as an enterprise expert and influence without authority
  • Exceptional written, verbal, and presentation skills
  • Willingness to travel up to approximately 30%
  • High level of integrity, ethics, compliance, and transparency, with flexibility to adapt to evolving scientific and organizational needs
  • Strong alignment with Dyne’s mission, values, and commitment to patients
Responsibilities
  • Serves as Dyne’s scientific and methodological leader for interventional, observational, and epidemiologic research, including Phase 3b, Phase 4, and prevalence/incidence studies, to address Medical Affairs–driven evidence needs across the portfolio
  • Partners with Medical Affairs and HEOR to develop and execute an enterprise-level epidemiology and RWE strategy aligned with organizational objectives
  • Establishes governance, best practices, and standards for epidemiologic and real world research across Medical Affairs
  • Provides expert guidance to Global Medical Directors and cross-functional teams on the appropriate use, interpretation, and limitations of real world data
  • Acts as an internal thought leader in epidemiology, RWE, and observational research methodologies
  • Leads the design, execution, and interpretation of epidemiologic and observational studies supporting Medical Affairs objectives, including chart reviews, post hoc analyses, prospective observational studies, investigator-initiated studies, Phase 3b/4 studies, and prevalence/incidence studies
  • Partners with Clinical Development and Biometrics to inform endpoint development, protocol design, and external control strategies that address key evidence needs for clinical decision-making
  • Ensures studies are scientifically rigorous, fit-for-purpose, compliant, and publication-ready
  • Oversees scientific dissemination through peer-reviewed publications, congress presentations, and external scientific engagement
  • Provides epidemiology and RWE leadership in support of Drug Safety and Pharmacovigilance activities
  • Partners with Drug Safety/Pharmacovigilance and Clinical Development to support safety surveillance, signal evaluation, and benefit–risk assessment
  • Designs and oversees post-authorization safety studies (PASS), registry-based safety evaluations, observational safety studies, and long-term safety assessments
  • Supports evaluation of safety signals through background incidence rate analyses, observed-to-expected analyses, and other epidemiologic approaches
  • Contributes epidemiologic expertise to risk management plans, safety specifications, and safety-related regulatory documentation, as appropriate
  • Collaborates with Global Medical Directors, HEOR, Regulatory Affairs, Value & Access, Commercial, and other partners to support asset-level integrated evidence plans
  • Engages with health authorities in collaboration with Regulatory Affairs on epidemiology- and RWE-related interactions
  • Builds and maintains relationships with external epidemiologists, academic collaborators, consortia, and patient registries
  • Strengthens epidemiology and RWE capabilities across Medical Affairs through training, mentorship, and knowledge sharing
  • Manages budgets, timelines, vendors, and external partners to ensure quality, compliance, and operational excellence
  • Monitors advances in real world data sources, analytics, and epidemiologic methods to drive innovation and continuous improvement

Dyne Therapeutics develops therapies for serious muscle diseases using its FORCE™ platform, which helps deliver oligonucleotide medicines to muscle tissue. Through a portfolio of experimental therapies, the company advances them in clinical trials (ACHIEVE and DELIVER) with the aim of treating rare muscle diseases. The product works by enhancing targeted delivery of oligonucleotides to muscle, enabling existing genetic medicines to reach affected tissues more effectively. Dyne differentiates itself by its proprietary FORCE™ technology and its focus on rare muscle diseases, positioning itself for growth as trials progress toward potential commercialization. The company’s goal is to bring effective treatments to patients and families affected by serious muscle diseases, expanding options as its therapies advance through development and, potentially, regulatory approval.

Company Size

201-500

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2017

Get referred to Dyne Therapeutics

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Preclinical data shows sustained dystrophin expression and muscle function improvement after single low dose[1].
  • ACHIEVE trial shows dose-dependent splicing correction and functional improvement in DM1 patients[3].
  • Dyne secured $400M debt facility to support US launches of DMD and DM1 therapies within two years[3]

What critics are saying

  • Sarepta's upadacersen dominates DMD market with 80% adoption, blocking Dyne's switch opportunities in 12–18 months
  • FDA rejection risk for accelerated approval due to inadequate Phase 1/2 data persists in 6–12 months
  • Dyne faces insolvency within 12 months if FDA denies approval due to $200M debt and equity dilution

What makes Dyne Therapeutics unique

  • Dyne's FORCE™ platform targets TfR-1 for precise oligonucleotide delivery to muscle and CNS[1][2].
  • Dyne pioneers low-dose, infrequent therapy for DM1 using FORCE™ platform validation[4][6].
  • Dyne advances clinical programs for DMD and DM1 with fast track and orphan drug designations[3].

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

0%

2 year growth

-3%
Dyne Therapeutics
Dec 10th, 2025
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock | Dyne Therapeutics, Inc.

(Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,980,478 shares of its common stock at a public offering price of $18.44 per share.